神經性厭食症有其慢性化及高共病性的特徵,並且患者高頻率地使用住院資源所以有必要發展更有效的療法來治療。低劑量的抗精神病藥物可能對於神經性厭食症患者的強迫思考、焦慮、近精神病性的思考有療效而第二代抗精神病藥物以其副作用少的優勢成為臨床關注的焦點除了體重增加的考量之外,olazapine副作用不比其他第二代抗精神病藥物多且對於激躁和情緒擺盪有等人滿意的療效,因此成為研究的重心;它的療效可能跟olazapine作用在多巴胺受體、血清素受體、腎上腺素受體以及蕈毒素受體等有關,但是也必須考慮研究報告的限制。以olazapine的療效為研究基礎,探討對神經性厭食症患者的病理激轉,進一步研擬降低患者失能程度的策略,將是開拓醫療領域的重要方向。
It is mandatory to develop effective treatment for anorexia nervosa (AN) owing to the chronic course, high comobidity rate, and high admission rate. Low dosage antipsychotic treatment has been shown to improve obsession, anxiety, and quasi-psychotic thought symptoms in patients with AN. Improved side effete profiles of second generation antipsychotics make them more attractive as potential therapies for AN. Olanzapine appears to be especially well suited as a potential therapy due to stronger association with body weight increase, similarity lo other second generation antipsychotics in other adverse effects, and its effectiveness in treating agitation and emotional lability. The response might be associated with the effect of olanzapine on dopaminergic receptors, serotonergic receptors, adrenergic receptors, and muscarinic receptors. The etiology of AN remains unclear. Although the effectiveness of olanzapine therapy appears promising, further study is needed. (Full text in Chinese)